Vectura Group announces Andrew Oakley to the Board as upcoming CFO

– UK, Chippenham – Vectura Group plc (LSE: VEC), announces that Andrew J. Oakley, former Chief Financial Officer (“CFO”) of Actelion Pharmaceuticals Ltd (SIX: ATLN) will succeed Paul Oliver as CFO, Executive Director, and Company Secretary effective from 1st January 2015.  

Prior to joining Vectura, Andrew gained considerable experience at two Swiss bio-pharmaceutical companies, including nearly 11 years at Actelion, a leading international biopharmaceutical company.  He joined Actelion as CFO in 2003 and during his tenure, the company enjoyed a period of strong growth, with sales rising more than ten-fold to CHF1.8bn in 2013.  During his time at Actelion, Andrew accumulated considerable transaction experience, including acquisitions, out-licensing and in-licensing deals.  After leaving Actelion in 2013, he served as CFO at privately held Swiss biotech Novimmune.

Before he joined Actelion, Andrew was at Accenture, and has also gained international experience having lived and worked in the US, Australia and the UK.  Andrew qualified as a Chartered Accountant in Australia and holds a MBA from London Business School.  

Dr Chris Blackwell, Chief Executive of Vectura: “We are delighted to welcome Andrew to Vectura at this exciting period in the Company’s growth plans.  Andrew is an established and well-regarded CFO who has gained considerable relevant experience within a leading European pharmaceutical company.  His strong financial control, market knowledge and transaction experience will be a considerable asset for Vectura. “The Board would like to thank Paul for his considerable contribution to the Company over the past eight years.  Since joining Vectura, Paul has contributed to the growth of Vectura and to the successful acquisitions and subsequent integrations of Innovata plc and Activaero GmbH.  We wish him continued success in his future career.”

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases).  This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.1

Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.  Vectura currently has disclosed development collaborations and license agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.